Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 1, 2007 (13 weeks)
Business Overview: Illumina is a leading developer of life science tools for genetic variation analysis. The quarter was defined by the completion of the acquisition of Solexa, Inc. on January 26, 2007, which added next-generation DNA sequencing capabilities to Illumina's portfolio. The company operates in a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenue | $72,150 | $29,102 |
| Net Loss | $(298,076) | $(104) |
| Net Loss Per Share (Basic & Diluted) | $(5.58) | $(0.00) |
| Operating Cash Flow | $14,643 | $2,360 |
| Cash and Cash Equivalents (End of Period) | $123,529 | $49,044 |
| Total Debt (Long-term + Current) | $400,073 | $63 |
| Goodwill | $248,543 | $2,125 |
Margins: Gross margin on product revenue decreased to 64.4% in Q1 2007 from 67.0% in Q1 2006, primarily due to inventory revaluation costs from the Solexa acquisition and increased stock-based compensation.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 148% year-over-year to $72.2 million. Product revenue surged 163% to $61.3 million, driven by higher consumable sales and the introduction of the Illumina Genome Analyzer.
- Acquisition Impact: The acquisition of Solexa resulted in a one-time, non-cash charge of $303.4 million for acquired in-process research and development (IPR&D), which was expensed immediately. This charge was the primary driver of the net loss.
- Debt Financing: In February 2007, the company issued $400 million in 0.625% Convertible Senior Notes due 2014. Net proceeds were approximately $390.7 million.
- Stock Repurchases: The company repurchased 7.4 million shares of common stock for approximately $250.9 million during the quarter, utilizing proceeds from the debt offering.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 95% to $23.6 million, and R&D expenses increased 94% to $16.0 million, largely due to the integration of Solexa and increased legal costs related to litigation.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The $303.4 million IPR&D charge is a non-recurring item directly tied to the Solexa acquisition. Pro forma results excluding this charge would have shown a net loss of only $2.3 million for the quarter.
- Legal Proceedings (Affymetrix): A jury returned a verdict on March 13, 2007, finding Illumina infringed on five Affymetrix patents, awarding approximately $16.7 million in retroactive damages. The trial is multi-phased; subsequent phases will address patent validity and enforceability. Illumina has not recorded a reserve for this loss as the outcome is uncertain and subject to appeal.
- Outlook: Management expects continued growth in product revenue driven by new product launches (BeadXpress System, Illumina Genome Analyzer) and an expanding installed base. However, they anticipate increased competition and price pressure in the genotyping market.
- Liquidity: As of April 1, 2007, the company held $326.8 million in cash, cash equivalents, and marketable securities. Management believes current resources are sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- IPR&D Charge: Verify the $303.4 million write-off of Solexa's in-process R&D and its impact on the reported net loss versus pro forma earnings.
- Affymetrix Litigation: Monitor the status of the second and third phases of the trial regarding patent validity, which could alter the $16.7 million damages award or result in an injunction.
- Convertible Notes: Review the terms of the $400 million convertible debt, specifically the conversion triggers and the associated hedge transactions designed to mitigate dilution.
- Integration Risks: Assess the progress of integrating Solexa's operations and the realization of anticipated synergies and cost savings.
- Stock Repurchases: Confirm the remaining authorization under the Rule 10b5-1 trading plan ($25 million remaining as of April 1, 2007) and future buyback activity.